PMID- 23382783
OWN - NLM
STAT- MEDLINE
DCOM- 20130930
LR  - 20211025
IS  - 1838-7640 (Electronic)
IS  - 1838-7640 (Linking)
VI  - 3
IP  - 1
DP  - 2013
TI  - CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and 
      therapeutic potential.
PG  - 26-33
LID - 10.7150/thno.4922 [doi]
AB  - Lung cancer is the second most common malignancy and the leading cause of 
      cancer-related death in the western world. Moreover, despite advances in surgery, 
      chemotherapy and radiotherapy, the death rate from lung cancer remains high and 
      the reported overall five-year survival rate is only 15%. Thus, novel treatments 
      for this devastating disease are urgently needed. Chemokines, a family of 48 
      chemotactic cytokines interacts with their 7 transmembrane G-protein-coupled 
      receptors, to guide immune cell trafficking in the body under both physiologic 
      and pathologic conditions. Tumor cells, which express a relatively restricted 
      repertoire of chemokine and chemokine receptors, utilize and manipulate the 
      chemokine system in a manner that benefits both local tumor growth and distant 
      dissemination. Among the 19 chemokine receptors, CXCR4 is the receptor most 
      widely expressed by malignant tumors and whose role in tumor biology is most 
      thoroughly studied. The chemokine CXCL12, which is the sole ligand of CXCR4, is 
      highly expressed in primary lung cancer as well as in the bone marrow, liver, 
      adrenal glands and brain, which are all sites for lung cancer metastasis. This 
      review focuses on the pathologic role of the CXCR4/CXCL12 axis in NSCLC and on 
      the potential therapeutic implication of targeting this axis for the treatment of 
      NSCLC.
FAU - Wald, Ori
AU  - Wald O
AD  - Department of Cardiothoracic Surgery, Hadassah University Hospital, Jerusalem, 
      Israel. ori.wald@mail.huji.ac.il
FAU - Shapira, Oz M
AU  - Shapira OM
FAU - Izhar, Uzi
AU  - Izhar U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130113
PL  - Australia
TA  - Theranostics
JT  - Theranostics
JID - 101552395
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Receptors, CXCR4)
SB  - IM
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*pathology
MH  - Chemokine CXCL12/*metabolism
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*pathology
MH  - Neoplastic Stem Cells/metabolism
MH  - Receptors, CXCR4/antagonists & inhibitors/*metabolism
PMC - PMC3563078
OTO - NOTNLM
OT  - Chemokines.
OT  - Human
OT  - Lung
OT  - NSCLC
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2013/02/06 06:00
MHDA- 2013/10/01 06:00
PMCR- 2013/01/01
CRDT- 2013/02/06 06:00
PHST- 2012/07/24 00:00 [received]
PHST- 2012/10/03 00:00 [accepted]
PHST- 2013/02/06 06:00 [entrez]
PHST- 2013/02/06 06:00 [pubmed]
PHST- 2013/10/01 06:00 [medline]
PHST- 2013/01/01 00:00 [pmc-release]
AID - thnov03p0026 [pii]
AID - 10.7150/thno.4922 [doi]
PST - ppublish
SO  - Theranostics. 2013;3(1):26-33. doi: 10.7150/thno.4922. Epub 2013 Jan 13.